Understand the source comparison
Semax Amidate Clinical Trials 2026 Comparison
Understanding how the active Semax Amidate clinical trials 2026 differ in design, patient population, and measured outcomes helps clarify which findings will generalise to broader cognitive enhancement applications versus condition-specific recovery protocols.
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Understanding how the active Semax Amidate clinical trials 2026 differ in design, patient population, and measured outcomes helps clarify which findings will generalise to broader cognitive enhancement applications versus condition-specific recovery protocols.
- Post-Stroke Cognitive Recovery
- 180 patients aged 50–75, ischemic stroke within 12 months
- 600 mcg intranasal twice daily
- MoCA score change from baseline
- 12 weeks + 4-week washout
- Randomised, double-blind, placebo-controlled
- Adult ADHD
- 120 patients aged 18–45, DSM-5 ADHD diagnosis, CAARS ≥65
- 300 mcg intranasal three times daily
- CAARS inattention subscale reduction
- 12 weeks per phase, crossover design
- Randomised, double-blind, placebo-controlled crossover
- Traumatic Brain Injury (Veterans)
- 60 military veterans, mild-moderate TBI within 5 years
- 900 mcg intranasal twice daily
- WAIS-IV processing speed index improvement
- 16 weeks, no washout
- Open-label, single-arm, exploratory efficacy
- The stroke trial's 600 mcg twice-daily dosing reflects earlier pilot data showing this regimen produced detectable plasma BDNF elevation without ceiling effects. Higher doses (1200 mcg twice daily) showed no additional BDNF increase, suggesting receptor saturation. The ADHD trial uses lower per-dose administration (300 mcg) but more frequent dosing (three times daily) to maintain steady dopaminergic modulation throughout waking hours, targeting attention span rather than memory consolidation. The TBI trial's 900 mcg dose is the highest tested in humans and reflects the exploratory nature of the protocol. The goal is to establish whether higher-dose regimens produce larger neuroplasticity effects measurable via DTI white matter fractional anisotropy changes.
- Patient eligibility criteria reveal important contraindications: all three Semax Amidate clinical trials 2026 exclude individuals with active seizure disorders (due to theoretical BDNF-mediated excitotoxicity risk in already hyperexcitable neurons), uncontrolled hypertension (systolic >160 mmHg), or concurrent use of monoamine oxidase inhibitors (MAOIs), which could potentiate the peptide's dopaminergic effects unpredictably. Pregnant or breastfeeding individuals are excluded due to absence of reproductive toxicology data. These exclusion criteria will likely carry forward into clinical use guidelines if Semax Amidate advances to Phase III trials and eventual regulatory review.